Robert Sebra, Ph.D. will lead Technology Development for Sema4 with technology adoption, and research and development to create high-throughput diagnostics and innovative IP. Dr. Sebra has vast experience in molecular, biochemical, and sequencing technology including surface bioconjugation techniques, lab-on-a-chip platforms, active biomaterials, single-molecule platforms, and the integration of bulk and single cell sequencing technologies for basic science and clinically driven applications. He is a leading expert in sequencing platforms and a pioneer in new approaches for single molecule and single cell assay development. Dr. Sebra has published more than 50 papers in top tier journals, including Science, Cell, Nature, NEJM, and Cancer Discovery, and his work has led to multiple issued patents.
Dr. Sebra will continue as the Director of Technology Development at the Icahn Institute of Genomics and Multiscale Biology and an Associate Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai in New York. Since establishing a team at Icahn School of Medicine at Mount Sinai, Dr. Sebra has applied WGS and targeted genomics approach toward a better understanding of genomic variation for higher resolution human disease diagnostics in cancer and inherited disease, alongside infectious disease surveillance using both long- and short-read sequencing techniques. Prior to his work at Sinai, Dr. Sebra was involved in research and development contributing to single molecule real-time long read sequencing technology and applications at Pacific Biosciences after receiving his Ph.D. in Chemical and Biological Engineering at University of Colorado, Boulder.